Clinical Trial: NCT04392505
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Oslo University Hospital |
| Information Provided By: | Oslo University Hospital |
| Last Update Posted: | 2024-02-29 |
Study Overview
Brief Summary
The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation.
The hypothesis is that clinical differences in course of disease reflect underlying biological characteristics.
Official Title
Conditions
Intervention / Treatment
- Drug: Durvalumab Injection
Other Study ID Numbers
- DART
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Oslo University Hospital |
| Information Provided By: | Oslo University Hospital |
| Last Update Posted: | 2024-02-29 |
Study Overview
Brief Summary
The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation.
The hypothesis is that clinical differences in course of disease reflect underlying biological characteristics.
Official Title
Conditions
Intervention / Treatment
- Drug: Durvalumab Injection
Other Study ID Numbers
- DART